Our InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients
Our US Medicare-reimbursed lead product InVisionFirst-Lung is already transforming the lives of advanced NSCLC patients
Our Mission
We are transforming the lives of cancer patients and their families through the power of liquid biopsy
Latest News and Events
Inivata and the European Organisation for Research and Treatment of Cancer (EORTC) collaborate in Phase II NSCLC study
Inivata to provide ctDNA liquid biopsy using its InVisionFirst®-Lung test to analyze resistance in patients treated with lorlatinib ... Read More
Clinical utility of ctDNA genomic alterations (GA) based on ESMO scale for clinical actionability of molecular targets (ESCAT) in advanced NSCLC
L. Mezquita, D. Planchard, M. Dorta, M. Aldea, C. Naltet, V. Lamberts, M. Grecea, P. Martin-Romano, F. de Kievit, C. Jovelet, E. ... Read More
Advances in Liquid Biopsies Conference
Event expiration date display - 13 - 16 JAN 2020
Location: California Read More
Changing Lives
Patients are at the heart of everything we do.
Our first product is for advanced Non-Small Cell lung Cancer and our world-leading tests are already impacting patients’ lives.
This is the story of the first patient Inivata tested.
